Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,304.62
(
-0.88%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
108.57
(
0.30%
)
Bitcoin
66,612.89
(
0.99%
)
News Focus
News Focus
Post# of 257313
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 103985

Wednesday, 02/08/2012 12:01:26 PM

Wednesday, February 08, 2012 12:01:26 PM

Post# of 257313
NVS reports additional Bexsero data in infants:

http://www.bloomberg.com/news/2012-02-07/novartis-s-bexsero-guards-infants-against-brain-swelling-malady-in-study.html

Bexsero is a meningococcal-B vaccine previously known as 4cMenB. As noted in #msg-54312729, there is no comparable product from any company, which is why NVS thinks it Bexsero can be a big seller.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today